Novavax COVID-19 Vaccine Becomes 5th to Reach Phase 3 Trial in the US
- 3 years ago
Novavax COVID-19 Vaccine Becomes
5th to Reach Phase 3 Trial in the US.
On Monday, Novavax announced the beginning
of its Phase 3 trial for its vaccine candidate,
named NVX-CoV2373, in the U.S. and Mexico.
This trial is a critical step in building the global portfolio of safe and effective vaccines to protect the world's population, Novavax President and CEO Stanley C. Erck, via news release.
The trial will evaluate safety, efficacy
and immune response in up to
30,000 people aged 18 and over.
The company also aims for at least
25% of participants to be age 65
or older and at least 15% to be Black.
Johnson & Johnson expects results from its Phase 3 trial
of a single-dose vaccine by January or February
5th to Reach Phase 3 Trial in the US.
On Monday, Novavax announced the beginning
of its Phase 3 trial for its vaccine candidate,
named NVX-CoV2373, in the U.S. and Mexico.
This trial is a critical step in building the global portfolio of safe and effective vaccines to protect the world's population, Novavax President and CEO Stanley C. Erck, via news release.
The trial will evaluate safety, efficacy
and immune response in up to
30,000 people aged 18 and over.
The company also aims for at least
25% of participants to be age 65
or older and at least 15% to be Black.
Johnson & Johnson expects results from its Phase 3 trial
of a single-dose vaccine by January or February